tbuckley/cabot-search huggingface dataset:
Mechanisms of the sensory effects of tacrolimus on the skin
Authors: U. Pereira, N. Boulais, N. Lebonvallet, J.P. Pennec, G. Dorange, L. Misery
Journal: British Journal of Dermatology (2010)

Journal Article Mechanisms of the sensory effects of tacrolimus on the skin Get access U. Pereira, U. Pereira University of Western Brittany, Laboratory of Neuronal Factors and Tissue Structure (EA 4326), Brest, France Search for other works by this author on: Oxford Academic Google Scholar N. Boulais, N. Boulais University of Western Brittany, Laboratory of Neuronal Factors and Tissue Structure (EA 4326), Brest, France Search for other works by this author on: Oxford Academic Google Scholar N. Lebonvallet, N. Lebonvallet University of Western Brittany, Laboratory of Neuronal Factors and Tissue Structure (EA 4326), Brest, France Search for other works by this author on: Oxford Academic Google Scholar J.P. Pennec, J.P. Pennec University of Western Brittany, Laboratory of Neuronal Factors and Tissue Structure (EA 4326), Brest, France Search for other works by this author on: Oxford Academic Google Scholar G. Dorange, G. Dorange University of Western Brittany, Laboratory of Neuronal Factors and Tissue Structure (EA 4326), Brest, France Search for other works by this author on: Oxford Academic Google Scholar L. Misery L. Misery University of Western Brittany, Laboratory of Neuronal Factors and Tissue Structure (EA 4326), Brest, FranceDepartment of Dermatology, University Hospital, 5 Avenue Foch, F‐29200 Brest, France Laurent Misery. E‐mail: laurent.misery@chu‐brest.fr Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 1, 1 July 2010, Pages 70–77, https://doi.org/10.1111/j.1365-2133.2010.09757.x Published: 01 July 2010
AR47A6.4.2, a naked monoclonal antibody targeting Trop-2, exhibits anti-tumor efficacy in multiple human cancer models as a monotherapeutic agent and demonstrates efficacy in combination therapy
Authors: Amandine Truong, Ningping Feng, Daad Sayegh, Baldwin Mak, Susan Hahn, Daniel Pereira, David Young
Journal: Cancer Research (2008)

3990  Trop-2 is a putative signal transduction molecule with widespread expression reported in a number of human carcinomas. Increasing evidence supports the role of Trop-2 in cancer, and over-expression studies suggest Trop-2 plays a role in cancer cell proliferation both in vitro and in vivo. In human colorectal cancer, high levels of Trop-2 have been associated with poor prognosis and a decrease in patient survival. Most recently, Trop-2 was suggested to play an important role in metastasis and high levels of Trop-2 were reported in metastatic tumors from breast cancer patients. Taken together, these findings suggest that targeting Trop-2 in cancer patients may be an effective therapeutic strategy. Using the ARIUS FunctionFIRST™ anti-cancer antibody discovery platform, AR47A6.4.2, a functional monoclonal antibody targeting human Trop-2, was identified.  To examine the potential anti-tumor effect of this antibody in vivo, AR47A6.4.2 was administered in both prophylactic and established xenograft models of human solid tumors. Significant tumor growth inhibition was observed in models of breast, pancreatic, colon, and prostate cancers, concomitant with an increase in the survival of mice in the antibody treatment groups. The potency of AR47A6.4.2 was enhanced in an established model of pancreatic cancer when administered in combination with Gemcitabine®, a standard of care in pancreatic cancer. The combination therapy resulted in tumor regression during the treatment period, and 97 % tumor growth inhibition was observed 27 days after treatment ended.  Mechanism of action studies have revealed that AR47A6.4.2 treatment diminishes MAPK phosphorylation in response to serum stimulation, suggesting that AR47A6.4.2 may exert some of its anti-tumor effects by inhibiting TROP-2 signaling and downstream phosphorylation of MAPK. In addition, in pancreatic cancer cell lines where AR47A6.4.2 has exhibited anti-tumor activity, AR47A6.4.2 was also shown to induce complement dependent cytotoxicity in vitro.  In summary, AR47A6.4.2, the first naked therapeutic antibody targeting Trop-2, demonstrates significant anti-tumor in vivo efficacy in xenograft models of human pancreatic, colon, breast and prostate cancer, thereby confirming its potential therapeutic value in treating these solid tumor malignancies. In addition, this antibody can be combined with chemotherapy to enhance its anti-tumor activity. Towards the goal of bringing AR47A6.4.2 to the clinic, the cynomolgus monkey has been identified as a relevant pre-clinical toxicology model and a humanized version of AR47A6.4.2 has been generated with high affinity and potent anti-tumor activity.
Özofageal Skuamöz Hücreli Neoplazmların Endoskopik Submukozal Diseksiyonu
Authors: Mitsuhiro Fujishiro, Naohisa Yahagi, Naomi Kakushima, Shinya Kodashima, Yosuke Muraki, Satoshi Ono, Nobutake Yamamichi, Ayako Tateishi, Yasuhito Shimizu, Masashi Oka, Keiji Ogura, Takao Kawabe, Masao Ichinose, sup> ve Masao Omata
Journal: Clinical Gastroenterology and Hepatology (2006)
Effect of all-trans retinoic acid (ATRA) on differentiation of dendritic and immature myeloid cells in cancer patients
Authors: Dmitry I. Gabrilovich, Noweeda Mirza, Ingo Fricke, Nickolas Williams, Scott Antonia, Mayer Fishman
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4877 

Abnormal differentiation of dendritic cells (DC) in cancer manifests in decreased presence and impaired function of mature DCs and the appearance of a larger number of immature myeloid cells (ImC) that are capable of suppressing antigen-specific T cells. Recently it becomes increasingly clear that success of immune intervention in cancer will depend on the ability to remove ImC and improve differentiation of DCs. Previous in vitro and in vivo studies in tumor-bearing mice suggested that all-trans-retinoic acid (ATRA) could improve DC differentiation and eliminate ImC. Here, we for the first time have tested the effect of ATRA on DCs and ImC in cancer patients. Eighteen patients with advanced stage renal cell carcinoma (RCC) were enrolled onto the study and received treatment with ATRA (50-150 mg/m2/day) for seven days. Seven days after completion of ATRA treatment patients started IL-2 therapy for five consecutive weeks. Peripheral blood was collected weekly. In parallel blood was collected from 16 patients that received IL-2 therapy alone. Control group comprised 7 healthy volunteers. Mononuclear cells (MNC) isolated at each time point were stored in liquid nitrogen. All samples from the same patient were analyzed simultaneously. After thawing MNC were cultured overnight and then were labeled with a cocktail of lineage specific antibodies (anti-CD3, CD19, CD56 and CD14), anti-HLA-DR antibody, anti-CD33 antibody, and either anti-CD86, anti-CD40, anti-CD83, or anti-CCR7 antibodies. ImC were defined as Lin negative, HLA-DR negative, CD33 positive cells. DCs were defined as lineage negative, HLA-DR positive cells. In addition, the presence of myeloid and plasmocytoid subsets of DCs was determined using anti-CD11c and anti-CD123 antibodies. Cells were evaluated by flow cytometry. The proportions of different populations of DCs were calculated. In addition the response of MNC to antigen (tetanus toxoid) and mitogen (PHA) was evaluated as well as the ability of DCs to stimulate allogeneic T cells. To date no adverse effect of the therapy was reported. This trial is at an early stage, however, the initial results are very encouraging. As expected almost all patients with metastatic RCC had increased level of ImC. ATRA treatment substantially decreased the number of ImC in more than 90% of them. In 60% of patients the presence of ImC was reduced to the control level. ATRA treatment substantially increased the proportion and functional activity of DCs. The presence of CD83+ or CD40+ mature DCs was also increased. These first results suggest that ATRA may substantially improve DC differentiation and eliminate ImC in cancer patients. It could be a valuable addition to different cancer immunotherapeutic strategies.
Long-Term Follow-Up of Idiopathic Ventricular Fibrillation Ablation
Authors: Sébastien Knecht, Frédéric Sacher, Matthew Wright, Mélèze Hocini, Akihiko Nogami, Thomas Arentz, Bertrand Petit, Robert Franck, Christian De Chillou, Dominique Lamaison, Jéronimo Farré, Thomas Lavergne, Thierry Verbeet, Isabelle Nault, Seiichiro Matsuo, Lionel Leroux, Rukshen Weerasooriya, Bruno Cauchemez, Nicolas Lellouche, Nicolas Derval, Sanjiv M. Narayan, Pierre Jaïs, Jacques Clementy, Michel Haïssaguerre
Journal: Journal of the American College of Cardiology (2009)
The Blocks Grandfather Carved
Authors: Walt McDonald
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes
Authors: Alexander E. Fraley, Gregory G. Schwartz, Anders G. Olsson, Scott Kinlay, Michael Szarek, Nader Rifai, Peter Libby, Peter Ganz, Joseph L. Witztum, Sotirios Tsimikas
Journal: Journal of the American College of Cardiology (2009)
A novel connection: Obstructive sleep apnoea and diabetic neuropathy
Authors: Nejat Altintas, Umit Tutar, Muzaffer Sariaydin, Raziye Tiras
Journal: European Respiratory Journal (2013)

Rationale: An ever-growing number of studies have shown that obstructive sleep apnoea(OSA) is associated with insulin resistance, glucose intolerance and type 2 diabetes, independent of obesity. OSA is associated with many of the pathophysiological deficits that are found in diabetes, it seems reasonable to speculate that OSA could play an important role in the development or progression of Diabetic peripheral neuropathy (DPN).

Objectives: To evaluate the relation between OSA and peripheral neuropathy in patients with type 2 diabetes.

Design: A cross-sectional study conducted between May 2011 and August 2012 in four hospitals in Turkey.

Patients And Methods: Three hundred forty six patients with type 2 diabetes mellitus were recruited. OSA was evaluated with overnight-attended polysomnography. DPN was diagnosed with electromyography, nerve conduction velocity tests, the Rochester Neuropathy Score method, the Michigan Neuropathy Screening Instrument.

Results: In the study population, 197( 57%) patients had OSA. The proportion of subjects with diabetic peripheral neuropathy in the different categories was 29.8% among subjects without OSA, 44.3% among those with mild to moderate disease, and 72.0% among those with severe OSA (p<0.001). In the multivariate logistic regression model, after adjustment for all significant univariate covariates, OSA was identified as independently associated with diabetic neuropathy (odds ratio: 3.07; 95% confidence interval, 1.32–5.64; P = 0.0027).

Conclusion: There is an independent association between OSA and diabetic peripheral neuropathy and the degree of AHI and the severity of nocturnal hypoxemia corralate with the severity of DPN.
Abstract 17711: Myocardial Long Non-coding RNA Expression Exhibits Chamber- and Disease-Specific Signatures in Human Right Ventricle
Authors: Kai-Chien Yang, Thomas G Di Salvo
Journal: Circulation (2014)

Background:  Eukaryotic genome transcription is pervasive; >90% of the mammalian genome is transcribed as long non-coding RNAs (lncRNAs). It is known that human cardiac lncRNA expression is dynamically regulated in the left ventricle (LV) with heart failure (HF). However, it remains unclear how lncRNA expression is regulated in normal and failing right ventricle (RV).   Methods & Results:  Paired-end RNA sequencing (RNASeq) was conducted using RNA isolated from paired RV and LV samples from non-failing (NF) hearts (n=5), as well as from the RVs of dilated non-ischemic (DCM, n=11) and ischemic (ICM, n=11) human failing hearts. A total of 970568044 read pairs were obtained. RNASeq analysis revealed high abundance of lncRNAs of mitochondrial origin in both RV (58.8%) and LV (56.5%). Among the 4129 lncRNAs significantly expressed (≥1 reads per killobase exon per million mapped reads) in human myocardium, 439 (10.6%) were differentially expressed (absolute fold-change≧1.2, adjusted P   Conclusion:  Human cardiac lncRNA expression exhibits chamber-specific signatures and discriminates RV from LV. RV lncRNAs are dynamically regulated with advanced HF, and the expression profiles of RV lncRNAs discriminate failing hearts of different etiologies. Taken together, these results suggest that lncRNAs may play an important role in shaping chamber-specific ventricular function and may contribute to etiology-specific RV remodeling processes during HF.
Abstract 559: Survival From Cardiovascular Events as Predicated by Carotid (Common Carotid Artery) Intima-media Thickness and Doppler Values in Ischaemic Chinese Patients Requiring Coronary Angiogram
Authors: Stephen Wai-luen Lee, Shun Ling Kong, Yui Ming Lam, William K Hau, Simon Lam, Jo Jo Hai, Michael Chan, Kelvin Chan, Linda Lam, Carmen Chan, Raymond T Cheung, Hung Fat Tse, Raymond H Chan
Journal: Circulation (2009)
Abstract 332: Differences in Vital Signs Between Elderly and Non-Elderly Patients Prior to Ward Cardiac Arrest
Authors: Matthew M Churpek, Trevor C Yuen, Christopher Winslow, Jesse B Hall, Dana P Edelson
Journal: Circulation (2014)

BACKGROUND: Vital signs and composite risk scores, such as the Modified Early Warning Score (MEWS), are used to identify high-risk patients, trigger rapid response teams, and assist with triage decisions. Although age-related vital sign changes are known to occur, little is known about the differences in vital signs between elderly and non-elderly patients prior to ward cardiac arrest (CA). We compared the accuracy of vital signs and the MEWS for detecting CA between elderly and non-elderly patients. METHODS: All patients hospitalized on the wards from five hospitals were included in the study. Patient characteristics and vital signs prior to CA were compared between elderly (age ≥65 years) and non-elderly (age &lt;65 years) patients. The area under the receiver operating characteristic curve (AUC) was also calculated for vital signs and the MEWS for elderly and non-elderly ward patients for CA. RESULTS: A total of 269,956 admissions with documented age occurred during the study period, which included 422 index ward CAs. Within four hours of CA, elderly patients had significantly lower mean heart rate (88 vs. 99 beats per minute; P&lt;0.001), diastolic blood pressure (60 vs. 66 mm Hg; P=0.007), and shock index (0.82 vs. 0.93; P&lt;0.001), and higher pulse pressure index (0.45 vs. 0.41; P&lt;0.001) and temperature (97.6 vs. 97.3 °F; P=0.047). The AUCs for all vital signs and the MEWS were higher for non-elderly patients than elderly patients (MEWS AUC 0.85 (95% CI 0.82-0.88) vs. 0.71 (95% CI 0.68-0.75); P&lt;0.001). While the incidence of CA increased with age, accuracy of the MEWS decreased (Figure). CONCLUSIONS: Vital signs are much more accurate for detecting CA on the wards in non-elderly patients compared to elderly patients, which has important implications for how they are used for identifying critically ill patients. Further investigation into improving the accuracy of risk stratification for elderly patients is necessary in order to decrease their risk for this devastating event.
Estrogen and Asymmetric Dimethylarginine in Postmenopausal Women
Authors: Kazushi Tsuda, Ichiro Nishio
Journal: Circulation (2004)

We read with great interest the recent article by Holden et al 1 dealing with the relationship between estrogen and asymmetric dimethylarginine (ADMA) metabolism in postmenopausal women.The results of their study demonstrated that hormone replacement therapy significantly decreased plasma ADMA levels in postmenopausal women.In an in vitro study, Holden et al 1 observed that estrogen increased the activity of dimethylarginine dimethylaminohydrolase activity in endothelial cells.They proposed that estrogen can alter the catabolism and release of ADMA, which might partially contribute to the positive effect of estrogen on NO synthesis.Several studies have already reported that ADMA might have a crucial role in cardiovascular regulations.It was demonstrated that inhibition of NO bioavailability by ADMA and a subsequent reduction in endothelial function might contribute to the increase in blood pressure during salt intake in normotensive postmenopausal women not receiving estrogen. 2Similarly, it was reported that there was a significant inverse correlation between plasma ADMA and flow-mediated dilatation of brachial artery, indicating that ADMA might be related to a decline in endothelial vasodilator function. 3 In a previous study, we showed that estrogen-induced improvement of membrane fluidity of erythrocytes was mediated by NO production, which was counteracted by ADMA in postmenopausal women. 4 The finding suggests that ADMA might actively participate in the regulation of cell membrane function in postmenopausal women.Because the deformability and microviscosity of erythrocyte membranes may be highly dependent on the membrane fluidity, the reduction in membrane fluidity could cause a disturbance in the blood rheological behavior and in the microcirculation, which might contribute to the pathophysiology of hypertension.Recently, Achan et al 5 demonstrated that intravenous infusion of ADMA increased blood pressure and systemic vascular resistance and decreased heart rate and cardiac output in humans.Therefore, we would like to know whether the hormone replacement therapy-induced decrease in plasma ADMA level might be accompanied by the changes in blood pressure and cardiac function.It would be important to assess more precisely whether ADMA may be involved in the cardiovascular disorders in postmenopausal women.
Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients
Authors: E Masselli, C Carubbi, G Gobbi, P Mirandola, D Galli, S Martini, S Bonomini, M Crugnola, L Craviotto, F Aversa, M Vitale
Journal: Leukemia (2015)
PROBLEMS OF PULMONARY TUBERCULOSIS IN GENERAL PRACTICE
Authors: Reginald Fitz
Journal: Annals of Internal Medicine (1933)

Article1 August 1933PROBLEMS OF PULMONARY TUBERCULOSIS IN GENERAL PRACTICEREGINALD FITZ, M.D.REGINALD FITZ, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-7-2-245 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptFor several years I have been physician to the students at the Harvard Medical School. This experience has led inevitably to a deep interest in the clinical manifestations of pulmonary tuberculosis. I have been dismayed at the seriousness of this disease as it is found in a general practice of this sort. I have been struck by its varied appearance and, above all, I have been impressed by the great responsibility resting upon the family doctor in regard to it. Upon him much depends regarding the early diagnosis of tuberculosis, and his advice on the problems arising in the regulation...Reference1. MARLOW FW: Miliary tuberculosis of lungs with recovery; report of 2 cases, Am. Rev. Tuberc., 1929, xix, 529-543. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, Massachusetts*Read before the American College of Physicians, Montreal, February 8, 1933. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1933Volume 7, Issue 2Page: 245-250KeywordsPrimary care ePublished: 1 December 2008 Issue Published: 1 August 1933 PDF downloadLoading ...
Abstract 4489: Transesophageal Echocardiography Evaluation of Percutaneous Repair of Mitral Valve Using CARILLON <sup>™</sup> Device. Single-Center Procedural Results in Consecutive Patients
Authors: Olga Jerzykowska, Piotr Kalmucki, Maciej Woloszyn, Tomasz Grotowski, Rafal Link, Piotr Smuszkiewicz, Tomasz Siminiak
Journal: Circulation (2008)

Background : Despite recent advancements, Functional Mitral Regurgitation (FMR), secondary to dilated cardiomyopathy remains a common clinical problem. Conventional cardiac surgery therapies have high procedural risk and therefore new techniques for percutaneous repair of mitral valve are being developed. Aim. The purpose of the study was to verify the acute efficacy of percutaneous mitral valve repair in patients with FMR by transesophageal echocardiography (TEE) Methods : We analyzed consecutive cases of percutaneous mitral valve repair with CARILLON ™ Mitral Contour System ™ (Cardiac Dimensions® Inc.) performed in a single center. The technique is based on implantation into the coronary venous system, where the device applies tension to the mitral ring in order to improve coaptation of the leaflets. TEE was performed during the procedure in the cath lab. Measurements before and immediately after the device release at the end of the procedure are given. Results The procedure was attempted in 17 cases of secondary MR with no apparent organic changes on the leaflets. Successful implantation of the device was performed in 13 patients (12M and 1F, aged 48 – 67 yrs). The TEE parameters of the MR significantly changed after the procedure as compared to before the procedure, including vena contracta (0.43±0.13 vs 0.68±0.16cm, p=0.024), EROA (0.21±0.06 vs 0.27±0.08cm 2 , p=0.019) and MR jet area/LA area (37.31 ±11,51 vs 53.82±14,14%, p=0.001). In 4 patients the device was recaptured due to compromised circumflex artery (3pts) and/or lack of measurable improvement in TEE (2 pts). No procedural complications were observed. Conclusion The implantation of CARILLON ™ system is feasible and safe in patients with Functional MR. Initial observations on efficacy justify completion of large clinical trials aiming at establishing the role of the technique in clinical practice.